PROGRAM CHAIRS
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts
Vishal Patel, MD
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Associate Professor of Dermatology & of Medicine/Oncology
George Washington University School of Medicine & Health Sciences
Washington, DC
PROGRAM OVERVIEW
This educational activity is designed for surgical dermatologists, Mohs surgeons, dermatologists, and other healthcare professionals who manage patients with advanced or metastatic basal cell carcinoma or cutaneous squamous cell carcinoma. Our goal is to help these clinicians better explain the risk assessment of patients with non-melanoma skin cancers (NMSCs) who may derive optimal benefit with new systemic therapies when compared to Mohs surgery, incorporate patient trials data for systemic immunotherapy into the treatment of both advanced cutaneous squamous cell carcinoma and basal cell carcinoma, and collaborate with other members of the NMSC healthcare team to provide a multidisciplinary approach to the development of treatment plans for individuals with high-risk NMSCs.
TARGET AUDIENCE
This activity is designed to meet the educational needs of surgical dermatologists, Mohs surgeons, dermatologists, and other healthcare practitioners who care for patients with advanced/metastatic basal cell carcinoma or cutaneous squamous cell carcinoma.
LEARNING OBJECTIVES
- Explain the risk-assessment of patients with non-melanoma skin cancers who may derive optimal benefit with new systemic therapies when compared to Mohs surgery
- Incorporate patient trials data for systemic immunotherapy into the treatment of both advanced cutaneous squamous cell carcinoma and basal cell carcinoma
- Collaborate with other members of the NMSC health care team to provide a multidisciplinary approach to the development of treatment plans for individuals with high risk NMSCs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| David M. Miller, MD, PhD, FAAD | Consulting fees/advisory board: Almirall, Bristol Myers Squibb, EMD Serono, Merck, Regeneron, Sanofi Genzyme Contracted research: Regeneron, Kartos Therapeutics, NeoImmuneTech, Inc., Project Data Sphere Ownership interest: Stock options from Checkpoint Therapeutics and Avstera Therapeutics |
| Vishal Patel, MD | Consulting fees: Regeneron, Sun Pharma, Almirall, Biofrontera, Palvella, Replimune Speakers bureau: Regeneron, Sun Pharma, Almirall Contracted research: Regeneron, Phio Ownership interest: Avstera, Thirona |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Andrew Grzybowski, Sr. Vice President, Educational Partnerships for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Abigail Dill, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 10, 2025
EXPIRATION DATE: June 10, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
